Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.41 |
| ▸ | ATR | Q13535 | 10/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29804494 | 1.00 | RXRA (0.50) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL18695454 | 0.90 | RXRA (0.58) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL29952266 | 0.90 | RXRA (0.58) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL18399121 | 0.83 | RXRA (0.53) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL30050315 | 0.83 | RXRA (0.53) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL18399007 | 0.81 | RXRA (0.56) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL30151185 | 0.81 | RXRA (0.56) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL2144678 | 0.81 | ALDH1A1 (0.50) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL17034421 | 0.81 | RXRA (0.50) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL21786656 | 0.81 | RXRA (0.50) | RXRARXRBRXRGALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4344702-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| EP-4344702-A2 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | Novartis AG (CH) | 2024-04-03 | — | — | EP | disclosed |
| EP-4076662-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-01-31 | — | — | EP | disclosed |
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | NOVARTIS AG (CH) | 2023-07-18 | — | — | US | disclosed |
| US-20220363670-A1 | Pyrazolyl derivatives useful as anti-cancer agents | NOVARTIS AG (CH) | 2022-11-17 | — | — | US | disclosed |
| EP-4076662-A1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-10-26 | — | — | EP | disclosed |
| CN-114929342-A | Pyrazolyl derivatives as anticancer agents | 诺华股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021124222-A1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021120890-A1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | PAK5, CYP51A1, SF3B5 | RXRA 3302/4885RXRB 3437/4885RXRG 3379/4885 |
| US-20220363670-A1 | Pyrazolyl derivatives useful as anti-cancer agents | PAK5, CYP51A1, SF3B5 | RXRA 3302/4885RXRB 3437/4885RXRG 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.